

October 31, 2025

## **Announcement of Incubation Research Agreement with Ciconia Bioventures Inc.**

Kyoto University (hereafter “the University”) announced today that it has entered into an incubation research agreement with Ciconia Bioventures Inc. (Headquarters: Fujisawa, Kanagawa; Representative Director: Toshio Fujimoto; hereafter “Ciconia”). This collaboration aims to foster the creation of startups capable of global expansion, based on drug discovery seeds originating from the University’s research.

Under this agreement, the University and Ciconia will jointly evaluate drug discovery-related research outcomes from both scientific and business perspectives, with the goal of incubating promising startup companies. The University will explore potential interdisciplinary collaboration across multiple faculties and graduate schools to establish a smooth and effective framework for mutual cooperation with Ciconia. Through these initiatives, Ciconia and the University aim to accelerate the social implementation of academic innovations and contribute to the advancement of Japan’s innovation ecosystem.

### **About Ciconia Bioventures Inc.**

Ciconia Bioventures is a joint venture company formed with investments from Takeda Pharmaceutical Company, Astellas Pharma Inc., and Sumitomo Mitsui Banking Corporation. The company aims to revitalize Japan’s drug discovery ecosystem by incubating innovative drug discovery seeds originating in Japan and creating globally competitive startup companies. Ciconia continues to embrace challenges as a key player in delivering innovation from Japan that will transform global healthcare.

### **Contact:**

Innovation Promotion, Institutional Advancement and Communications, Kyoto University  
[biohubcollab@contracts.med.kyoto-u.ac.jp](mailto:biohubcollab@contracts.med.kyoto-u.ac.jp)  
TEL: .075-751-0909 (Medical division)

Ciconia Bioventures Inc.  
E-mail: [info@ciconiabiotechnures.com](mailto:info@ciconiabiotechnures.com)